KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $115.6 million.

  • Novavax's Accumulated Expenses fell 4714.23% to $115.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.6 million, marking a year-over-year decrease of 4714.23%. This contributed to the annual value of $211.2 million for FY2024, which is 4649.55% down from last year.
  • Per Novavax's latest filing, its Accumulated Expenses stood at $115.6 million for Q3 2025, which was down 4714.23% from $86.7 million recorded in Q2 2025.
  • Novavax's Accumulated Expenses' 5-year high stood at $673.7 million during Q4 2021, with a 5-year trough of $86.7 million in Q2 2025.
  • Its 5-year average for Accumulated Expenses is $344.6 million, with a median of $311.2 million in 2023.
  • In the last 5 years, Novavax's Accumulated Expenses surged by 138551.58% in 2021 and then crashed by 6526.57% in 2024.
  • Quarter analysis of 5 years shows Novavax's Accumulated Expenses stood at $673.7 million in 2021, then dropped by 12.26% to $591.2 million in 2022, then crashed by 33.24% to $394.7 million in 2023, then tumbled by 46.5% to $211.2 million in 2024, then tumbled by 45.26% to $115.6 million in 2025.
  • Its Accumulated Expenses stands at $115.6 million for Q3 2025, versus $86.7 million for Q2 2025 and $132.2 million for Q1 2025.